US FDA approves Samsung Bioepis and Biogen’s Byooviz
The US Food and Drug Administration (FDA) has approved Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab). Byooviz is an anti-vascular endothelial growth factor (VEGF)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.